Clinical characteristics of antidepressant use and related manic switch in bipolar disorder

References

1. ↵
   1. Miller S,
   2. Dell'Osso B,
   3. Ketter TA

   (2014) The prevalence and burden of bipolar depression. J Affect Disord 169, S3–S11.
2. ↵
   1. Strakowski SM

   (2007) Approaching the challenge of bipolar depression:results from STEP-BD. Am J Psychiatry 164, 1301–1303.
3. ↵
   1. Pacchiarotti I,
   2. Bond DJ,
   3. Baldessarini RJ,
   4. Nolen WA,
   5. Grunze H,
   6. Licht RW,
   7. et al.

   (2013) The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170, 1249–1262.
4. ↵
   1. Yatham LN,
   2. Kennedy SH,
   3. Parikh SV,
   4. Schaffer A,
   5. Beaulieu S,
   6. Alda M,
   7. et al.

   (2013) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder:update 2013. Bipolar Disord 15, 1–44.
5. ↵
   1. Geddes JR,
   2. Miklowitz DJ

   (2013) Treatment of bipolar disorder. Lancet 381, 1672–1682.
6. ↵
   1. Liu B,
   2. Zhang Y,
   3. Fang H,
   4. Liu J,
   5. Liu T,
   6. Li L

   (2017) Efficacy and safety of long-term antidepressant treatment for bipolar disorders - A meta-analysis of randomized controlled trials. J Affect Disord 223, 41–48.
7. ↵
   1. Baldessarini RJ,
   2. Leahy L,
   3. Arcona S,
   4. Gause D,
   5. Zhang W,
   6. Hennen J

   (2007) Patterns of psychotropic drug prescription for U.S patients with diagnoses of bipolar disorders. Psychiatr Serv 58, 85–91.
8. ↵
   1. Grande I,
   2. de Arce R,
   3. Jiménez-Arriero MÁ,
   4. Lorenzo FG,
   5. Valverde JI,
   6. Balanzá-Martínez V,
   7. et al.

   (2013) Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). Int J Neuropsychopharmacol 16, 513–523.
9. ↵
   1. American of Psychiatric Association

   (2013) Diagnostic and Statistical Manual of Mental Disorders 5th (DSM-5) (American Psychiatric Pub, Washington (DC)).
10. ↵
    1. Hayasaka Y,
    2. Purgato M,
    3. Magni LR,
    4. Ogawa Y,
    5. Takeshima N,
    6. Cipriani A,
    7. et al.

    (2015) Dose equivalents of antidepressants:Evidence-based recommendations from randomized controlled trials. J Affect Disord 180, 179–184.
11. ↵
    1. Sachs GS

    (1996) Mood chart. Unpublished assessment measure. The Harvard Bipolar Research Program (Massachusetts General Hospital, Boston (MA)).
12. ↵
    1. Vieta E,
    2. Nieto E,
    3. Autet A,
    4. Rosa AR,
    5. Goikolea JM,
    6. Cruz N,
    7. et al.

    (2008) A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry 9, 219–224.
13. ↵
    1. Grunze H,
    2. Vieta E,
    3. Goodwin GM,
    4. Bowden C,
    5. Licht RW,
    6. Möller HJ,
    7. et al.

    (2013) The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders:Update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14, 154–219.
14. ↵
    1. Truman CJ,
    2. Goldberg JF,
    3. Ghaemi SN,
    4. Baldassano CF,
    5. Wisniewski SR,
    6. Dennehy EB,
    7. et al.

    (2007) Self-reported history of manic/hypomanic switch associated with antidepressant use:data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 68, 1472–1479.
15. ↵
    1. Ghaemi SN,
    2. Hsu DJ,
    3. Soldani F,
    4. Goodwin FK

    (2003) Antidepressants in bipolar disorder:the case for caution. Bipolar Disord 5, 421–433.
16. ↵
    1. Amsterdam JD,
    2. Lorenzo-Luaces L,
    3. Soeller I,
    4. Li SQ,
    5. Mao JJ,
    6. DeRubeis RJ

    (2015) Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression:A randomized, double-blind, parallel-group, prospective study. J Affect Disord 185, 31–37.
17. ↵
    1. Vöhringer PA,
    2. Ostacher MJ,
    3. El-Mallakh RS,
    4. Holtzman NS,
    5. Thommi SB,
    6. Whitham EA,
    7. et al.

    (2015) Antidepressants in Type II Versus Type I Bipolar Depression:A Randomized Discontinuation Trial. J Clin Psychopharmacol 35, 605–608.
18. ↵
    1. Tohen M,
    2. Vieta E,
    3. Calabrese J,
    4. Ketter TA,
    5. Sachs G,
    6. Bowden C,
    7. et al.

    (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60, 1079–1088.
19. ↵
    1. Viktorin A,
    2. Lichtenstein P,
    3. Thase ME,
    4. Larsson H,
    5. Lundholm C,
    6. Magnusson PK,
    7. et al.

    (2014) The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 171, 1067–1073.
20. ↵
    1. Bottlender R,
    2. Rudolf D,
    3. Strauss A,
    4. Möller HJ

    (2001) Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 63, 79–83.
21. ↵
    1. Mundo E,
    2. Cattaneo E,
    3. Russo M,
    4. Altamura AC

    (2006) Clinical variables related to antidepressant-induced mania in bipolar disorder. J Affect Disord 92, 227–230.
22. ↵
    1. Berkol TD,
    2. Balcioglu YH,
    3. Aytac HM,
    4. Kirlioglu SS,
    5. Islam S,
    6. Ozyildirim I

    (2017) Maintenance treatment trends, therapeutic outcomes and their association with clinical features in remitted bipolar disorder. JNBS 4, 134–137.
23. ↵
    1. Berkol TD,
    2. Kirlioglu SS,
    3. Balcioglu YH,
    4. Ustun N,
    5. Islam S,
    6. Ozyildirim I

    (2017) Comparison of sociodemographic and clinical characteristics of bipolar patients with and without seasonal patterns. Anadolu Psikiyatr Derg 18, 571–576.
24. ↵
    1. Blanco C,
    2. Laje G,
    3. Olfson M,
    4. Marcus SC,
    5. Pincus HA

    (2002) Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 159, 1005–1010.
25. ↵
    1. Bowden CL,
    2. Gitlin MJ,
    3. Keck PE,
    4. Suppes T

    , eds (2010) Treatment of patients with Bipolar Disorder (American Psychiatric Association), Second Edition, 1–82.
26. ↵
    1. Joffe RT,
    2. MacQueen GM,
    3. Marriott M,
    4. Young LT

    (2005) One-year outcome with antidepressant--treatment of bipolar depression. Acta Psychiatr Scand 112, 105–109.
27. ↵
    1. Wada K,
    2. Sasaki T,
    3. Jitsuiki H,
    4. Yoshimura Y,
    5. Erabi H,
    6. Hada Y,
    7. et al.

    (2006) Manic/hypomanic switch during acute antidepressant treatment for unipolar depression. J Clin Psychopharmacol 26, 512–515.
28. ↵
    1. Ghaemi SN,
    2. Hsu DJ,
    3. Thase ME,
    4. Wisniewski SR,
    5. Nierenberg AA,
    6. Miyahara S,
    7. et al.

    (2006) Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. Psychiatr Serv 57, 660–665.
29. ↵
    1. Visser HM,
    2. Van Der Mast RC

    (2005) Bipolar disorder, antidepressants and induction of hypomania or mania. A systematic review. World J Biol Psychiatry 6, 231–241.
30. ↵
    1. Leverich GS,
    2. Altshuler LL,
    3. Frye MA,
    4. Suppes T,
    5. McElroy SL,
    6. Keck PE Jr.,
    7. et al.

    (2006) Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 163, 232–239.
31. ↵
    1. Henry C,
    2. Sorbara F,
    3. Lacoste J,
    4. Gindre C,
    5. Leboyer M

    (2001) Antidepressant-induced mania in bipolar patients:identification of risk factors. J Clin Psychiatry 62, 249–255.